Search Results for

Clear All Filters

July 26, 2022

Timi Iwayemi

Letter

CoronavirusIntellectual PropertyPharma

Activists to Biden: Share Walter Reed Army Vaccine With the World

If the Walter Reed vaccine proves effective against Covid-19 and its variants in further tests, it will be a vaccine wholly created by a public institution through use of public funds. Every aspect of the vaccine production process should be widely and freely shared to ensure globally distributed manufacturing. Widespread, equitable availability of effective vaccines at truly affordable prices would go a long way in achieving your stated goal of vaccinating the world.

July 26, 2022

Timi Iwayemi

Press Release

CoronavirusIntellectual PropertyPharma

Advocates to President Biden: Don’t Give Away New Publicly-Owned Coronavirus Vaccine Technology to Corporations

In advance of the White House Summit on the Future of COVID-19 Vaccines today, 29 groups including Public Citizen, Demand Progress and Revolving Door Project, a project of the Center for Economic and Policy Research, sent a letter to President Joe Biden urging him to ensure that pan coronavirus vaccine technology currently under development by the U.S. military remain public, and shared with the world.

April 25, 2022 | The American Prospect

Max Moran Fatou Ndiaye

Op-Ed

Congressional OversightPharma

Where's The Congressional Champion On Pharma Patent Abuses?

But for all of this, neither party’s congressional leaders have directly challenged the main legal mechanism that accounts for those high costs—namely, intellectual property. You’d think members of Congress would recognize the political salience of picking a fight with one of the most hated industries in America. So why isn’t anyone on Capitol Hill even talking about intellectual property’s role in driving high drug prices, and taking the PTO to task to do something about it?

October 29, 2021 | The American Prospect

Fatou Ndiaye Toni Aguilar Rosenthal

Op-Ed

Executive BranchPharmaRevolving Door

Will Biden’s FDA Be Led by a Pharma Guy?

Dr. Robert Califf appears to be the clearest front-runner for the (somehow) still open position of commissioner of the Food and Drug Administration. After floating his name in the press a few weeks ago, President Biden recently met with Califf in private. Such meetings tend to be the final step before a nominee is announced.

There’s just one problem: Califf is a longtime political consultant to Big Pharma and, more recently, to Big Tech. In fact, he’s so tied to those industries that he once earned the ire of a certain crucial senator from West Virginia.

September 29, 2021 | The American Prospect

Fatou Ndiaye Timi Iwayemi

Op-Ed

CoronavirusForeign PolicyPharmaTrade Policy

How to Vaccinate the World

When United States Trade Representative Katherine Tai announced this past May that the U.S. would support the TRIPS waiver on COVID-19 vaccines at the World Trade Organization (WTO), we at the Revolving Door Project celebrated the administration’s decision as “a transformative, hopeful event.” The waiver proposal calls on the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council to suspend intellectual-property protections on COVID-19 therapeutics, diagnostics, and vaccines to ensure materials necessary for combating the pandemic are “available promptly, in sufficient quantities and at affordable price to meet global demand.”

July 22, 2021

Timi Iwayemi Fatou Ndiaye

Report

Anti-MonopolyIndependent AgenciesIntellectual PropertyPharmaTrade Policy

The Industry Agenda: Big Pharma

In 2019, Gallup found that the pharmaceutical industry was “the most poorly regarded industry in Americans’ eyes,” and rightfully so. Pharmaceutical companies often set drug prices exorbitantly high, including life-saving drugs which patients literally cannot go without, such as insulin. This includes older drugs that are cheaper to produce — such as epinephrine (emergency medication used to treat severe allergic reactions and asthma attacks). These firms achieve this by stifling competition at the consumer’s expense, jealously protecting their money-makers from the generics which the pharmaceutical system is supposed to develop after a patent expires.

May 17, 2021

Fatou Ndiaye

Blog Post

2020 Election/TransitionIntellectual PropertyPharma

Revolver Spotlight: Kevin Rhodes

When choosing the next PTO director, the Biden administration should rule out those who have a history of prioritizing profits and corporate interests over public health and safety. One such individual is Kevin Rhodes, an ally of Big Pharma who has vigorously defended efforts to keep drug prices high. His current employer, 3M, has abused its monopoly on the military earplug market to sell overpriced and faulty products to veterans. This should be immediately disqualifying for any future PTO director. Here are a few of the most alarming aspects of Kevin Rhodes’s career: